Bio-Rad Launches TrailBlazer Tag and TrailBlazer StarBright Dye Label Kits for Antibody Conjugation to StarBright Dyes
New Kits Offer Broad Antibody Compatibility and Long-Term Stability for Flow Cytometry and Western Blot Applications
HERCULES, Calif. — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of its TrailBlazer™ Tag and TrailBlazer StarBright™ Dye Label Kits. The new kits offer a convenient method to label any antibody with one of Bio-Rad’s StarBright Dyes, for use in either flow cytometry or fluorescent western blot experiments.
The new two-kit system provides researchers across academia, pharma, and biotech access to Bio-Rad’s StarBright Blue and StarBright Violet Dyes, employing Bio-Rad’s SpyTag and SpyCatcher technology to conjugate a dye to an antibody of choice. This enables the design and generation of bespoke, flexible high-plex panels for flow cytometry and easy multiplex integration for fluorescent western blots.
“The new TrailBlazer Tag and StarBright Dye Label Kits are designed for researchers who require greater flexibility in their multiplex experiments, providing multiple label color palette options and access to a select range of our unique StarBright Blue and StarBright Violet Dyes, with additional dyes to be added to the range in the near future,” said Hilary Mavor, Marketing Director, Life Science Group, Bio-Rad. “With an easy-to-follow protocol and minimal hands-on time, the kits offer a simple process, resulting in user-independent, consistent, high-quality conjugated antibodies.”
Bio-Rad’s range of StarBright Dyes, proprietary fluorescent nanoparticles conjugated to flow-validated antibodies against key immunological targets, offers researchers exceptional brightness with narrow excitation and emission profiles for precise resolution. StarBright Dyes are compatible with most experimental protocols and flow cytometers, including the Bio-Rad ZE5 Cell Analyzer, without the need for special buffers, providing highly sensitive fluorescent detection, improving resolution of specific cell populations, and minimizing spillover and spreading. For fluorescent western blots, StarBright Blue 700 and 520, designed to work with the configuration of the ChemiDoc™ MP and ChemiDoc Go Imagers, are labeled to anti-mouse and anti-rabbit secondary antibodies, facilitating bright, highly sensitive fluorescent detection with short exposure times.
To learn more about Bio-Rad’s TrailBlazer Tag and StarBright Dye Label Kits, visit bio-rad-antibodies.com/SBlabelkits.
Bio-Rad’s TrailBlazer Tag and StarBright Dye Label Kits are currently available in the US and Canada only.
BIO-RAD, CHEMIDOC, and STARBRIGHT are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions. TRAILBLAZER is a trademark of Bio-Rad Europe GmbH in certain jurisdictions.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,700 employees and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.
Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include global economic and geopolitical conditions, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.